Navigation Links
Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
Date:9/28/2007

disease in two, non-treated tumours at one, two and three months post treatment.

The squamous cell scalp patient experienced stable disease in the target tumour for two months which then became a partial response at three months. This patient also experienced stable disease in one non-treated tumour measured at three months post-treatment. Patients in the Ib portion received either two, four or six intratumoural doses of REOLYSIN at 1x1010 TCID50 with a constant localized radiation dose of 36 Gy given in 12 fractions. Of the six patients who have completed the study to date, three patients (colorectal, melanoma and lung cancer) experienced tumour regression in the target tumour, as well as stable disease in non-treated tumours.

The colorectal patient experienced a partial response with a more than 50% regression in the target tumour as well as stable disease in four, non-treated tumours measured at one month following treatment. A melanoma patient experienced minor regression in the target tumour as well as stable disease in two, non-treated tumours at one and two months following treatment. A lung cancer patient experienced minor regression in the target tumour, as well as stable disease in three, non-treated tumours at two months following treatment.

The treatment has been well tolerated, with mostly Grade 1 or 2 toxicities noted including fatigue, lymphopenia, fever, and neutropenia. Grade 3 toxicities including cellulitis, dysphasia and diarrhoea were related to disease progression and not to the combination treatment. Viral replication was unaffected by cellular irradiation.

The primary objective of the Phase Ia/Ib trial is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of REOLYSIN when administered intratumourally to patients receiving radiation treatment. A secondary objective is to examine any evidence of anti-tumour activity. Eligible patients include those who have been diagnosed
'/>"/>

Contact: Cathy Ward
cathy.ward@oncolytics.ca
403-670-7370
Oncolytics Biotech Inc.
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Biotechnology industry expected to grow into a three billion dollar industry by 2002
2. Biotechnology on the lead
3. Panacea Biotech To Market Anthrax Vaccine
4. Commercialization of Biotech Discoveries, An Encouragement For Researchers
5. Biotech drug causing anemia-EPREX
6. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
7. Biologicals Transfer Proposal between US and Indian Biotechnology
8. Finland and India to interact and cooperate in the filed of telemedicine and biotechnology
9. Vical Biotech and NIH jointly develops HIV vaccine
10. Biotechnology Initiatives Planned In Hyderabad
11. Biotech Osiris to go public
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 With Thousand Oaks cosmetic ... the prosthodontists at the Anacapa Dental Art Institute in Woodland ... can be daunting for some. , That is why they ... they offer. , “No dentist wants cost to come between ... teeth,” said Dr. Mamaly Reshad, partner in the Anacapa Dental ...
(Date:11/26/2014)... ISI Telemanagement Solutions, Inc., a ... award the 2014 Lync Pioneer Award ... as a great honor to ISI, who continues ... Specifically, ISI offers an integrated collaboration reporting and ... including voice, video, Lync IM, and conferencing. ...
(Date:11/26/2014)... 2014 Bunion Bootie, the newest and ... an early celebration of the early holiday shopping season. ... at the promotional price of $29.95 each (normally $33.95 ... to any automatic discounts applied when buying more than ... for complete details. It’s simple: purchasing more Bunion ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, ... Distinguished Preceptorship Award from The American Association ... the advancement of nurse practitioners. The Distinguished Preceptorship ... had made a significant contribution toward increasing the ... of Nurse Practitioners (AANP) is the largest full-service ...
(Date:11/26/2014)... -- Teens prescribed anti-anxiety or sleep medications are ... other teens, a new study warns. The ... assessments on teenagers before prescribing these drugs to ... don,t realize the abuse potential," said lead researcher ... Michigan School of Nursing. "These drugs produce highly ...
Breaking Medicine News(10 mins):Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... -- How children respond to the smell of alcoholic ... according to a new study from the Monell Chemical ... of beer and an unpleasant odor, children of mothers ... of Non-escape drinkers to choose the unpleasant odor. , ...
... 2007 State policies have a significant impact on ... could play a key role in efforts to expand ... study in the June issue of the Journal ... are uniquely positioned to institute specific policy proscriptions emanating ...
... perform most, but safety an issue in poorer areas, ... About 234 million major surgeries are performed worldwide each ... countries than in low-income countries, U.S. researchers report. , ... Health, and his colleagues defined major surgeries as any ...
... ANN ARBOR, Mich., June 25 HealthMedia(R), Inc.,s,Succeed(TM) ... Products (HIP) Certification from the National Committee for,Quality ... about,health care quality. As a result, health plans ... for using the Succeed,HRA, since responsibility for adherence ...
... of the ACL TOP Family -, LEXINGTON, Mass., June ... FDA clearance 510(k) for the ACL,TOP software V3.0.0. This clearance ... System in the United States as a member of the ... as the other members of the ACL,TOP Family, including the ...
... Dr. Hilton Becker M.D.,F.A.C.S., F.R.C.S. of Boca Raton, Florida, ... 20 years, has created his most effective,implant yet -- the ... adjust in both shape and size after it has been ... are disappointed with,the shape and size of the breast after ...
Cached Medicine News:Health News:Kids connect alcohol odors with mom's emotions 2Health News:State policies influence drug treatment programs 2Health News:Worldwide Surgery Rates Tied to Economic Status 2Health News:HealthMedia Health Risk Assessment Earns Prestigious NCQA Certification 2Health News:Instrumentation Laboratory Launches ACL Top(R) 500 CTS Hemostasis Testing System 2Health News:Boca Raton Based Plastic Surgeon Introduces Revolutionary New Adjustable Breast Implant to Europe and Asia 2
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
(Date:11/26/2014)... 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, ... Dr. Helen Torley , President and Chief Executive ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:11/24/2014)... Juno Therapeutics today announced that the ... company,s JCAR015 chimeric antigen receptor product candidate.  The ... refractory B-cell acute lymphoblastic leukemia and was filed ... Center, where Phase 1 clinical trials are currently ... important news for patients who may benefit from ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
For the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses....
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Medicine Products: